Biocon sees larger licensing income from pharma

Biocon , India’s top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said.
The Bangalore-based drugmaker earlier said consolidated net profit fell 15.8 percent in December quarter, while revenue rose 3 percent. The sales growth in the fiscal third quarter ended December 31 was flat on lower licensing income.The company said, licensing fees and income dropped to 292 million rupees in October-December from 768 million rupees a year earlier.

Biocon’s presence straddles four main therapeutic areas – Diabetology, Cardiology, Nephrology and Oncology – even as it plans to introduce two new divisions, Comprehensive Care, and Immunotherapy, this year.

One thought on “Biocon sees larger licensing income from pharma

  • June 23, 2018 at 12:43 pm

    FIcRtW Wohh precisely what I was looking for, appreciate it for posting.

Leave a Reply

Your email address will not be published.